BALAXI PHARMACEUTICALS LIMITED Stock Price Today (NSE: BALAXI)

BALAXI PHARMACEUTICALS LIMITED

23.33+0.21 (+0.91%)
Market Closed

Fundamental Score

...

BALAXI PHARMACEUTICALS LIMITED Share Price — Live NSE/BSE Price, Fundamentals & Analysis

BALAXI PHARMACEUTICALS LIMITED share price today is 23.33, up +0.91% on NSE/BSE as of 16 September 2026. BALAXI PHARMACEUTICALS LIMITED (BALAXI) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of 128.80 (Cr). The 52-week high for BALAXI share price is 47.71 and the 52-week low is 15.20. At a P/E ratio of 51.84x, BALAXI is currently trading above its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 0.59% and a debt-to-equity ratio of 0.22.

BALAXI PHARMACEUTICALS LIMITED Share Price Chart — NSE/BSE Historical Performance

No data
High
26.99
Low
21.50
Volume
57.8K
Change
-2.15%

BALAXI PHARMACEUTICALS LIMITED share price chart: -2.15% return over the past month. 52-week high ₹47.71, 52-week low ₹15.20.

BALAXI PHARMACEUTICALS LIMITED — Last 10 Trading Days

DateOpenHighLowCloseVolume
23.0124.3322.5023.3319.59K (Cr)
24.8024.8023.0023.1226.07K (Cr)
23.4024.6922.7523.3939.70K (Cr)
24.2024.3622.7323.2439.29K (Cr)
24.1825.0522.7023.6887.55K (Cr)
24.2424.7523.2023.3467.89K (Cr)
26.0026.0023.5024.2469.37K (Cr)
26.6026.6024.9325.3750.78K (Cr)
26.9926.9924.4125.802.23L (Cr)
22.4525.0422.4525.013.03L (Cr)

BALAXI PHARMACEUTICALS LIMITED — Last 12 Months Price History

MonthOpenHighLowCloseChange
22.3526.9922.3523.33+4.38%
23.6725.4021.5022.34-5.62%
23.8725.5023.0023.90+0.13%
27.5027.5022.5023.91-13.05%
27.1029.9023.4026.21-3.28%
16.0328.6316.0326.63+66.13%
20.0020.9015.2015.67-21.65%
25.1325.8819.6019.73-21.49%
27.6329.9023.0124.38-11.76%
36.9537.2225.8626.87-27.28%
42.9443.8535.6736.75-14.42%
43.9945.3440.7642.94-2.39%

Returns & Performance

Poor

Return on Equity (ROE)

0.59%

Profit generated per ₹1 of shareholder equity

Poor

Return on Capital (ROCE)

3.47%

Returns generated on total capital deployed

Good

Oper. Profit Margin (5Y Avg)

11.12%

Average operating profit margin over 5 years

Dividend Yield

0.00%

Annual dividend as % of current share price

BALAXI PHARMACEUTICALS LIMITED Valuation Check

Poor

Price to Earnings (P/E)

51.84x

Share price ÷ earnings per share. Lower = cheaper

Poor

Industry Avg P/E

34.89x

Average P/E of all peers in this sector

Market-cap Classification
Small-cap
Higher growth potential with higher volatility.

Shareholding Pattern

Excellent

Promoter Holding

65.99%

% shares held by company founders/management

Poor

FII Holding

0.00%

% shares held by foreign institutional investors

Poor

DII Holding

2.56%

% held by domestic mutual funds, LIC, banks

Excellent

Promoter Pledged %

0.00%

% of promoter shares pledged as collateral — lower is safer

Growth Engine

Poor

Profit Growth (Quarterly YoY)

-92.94%

Net profit growth vs same quarter last year

Poor

Revenue Growth (Quarterly YoY)

14.05%

Revenue growth vs same quarter last year

Poor

Revenue Growth (5-Year CAGR)

3.15%

Compounded annual revenue growth over 5 years

Poor

EPS Growth (5-Year CAGR)

-63.13%

Earnings per share growth over 5 years

Poor

Net Profit Growth (5-Year CAGR)

-47.99%

Compounded annual net profit growth over 5 years

Balance Sheet Health

Excellent

Debt to Equity Ratio

0.22x

Total debt ÷ equity. Below 0.5 = financially healthy

Poor

Interest Coverage Ratio

2.36x

EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably

Free Cash Flow (5-Year Total)

-74.93 (Cr)

Cash left after capex over 5 years. Positive = self-funded growth

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

BALAXI PHARMACEUTICALS LIMITED Fundamental Analysis & Valuation Benchmarking

Educational evaluation of BALAXI across key market metrics for learning purposes.

Positive Indicators

4 factors identified

Conservative Debt Levels (D/E: 0.22)

Observation: Low leverage provides financial flexibility and reduced risk.

Analysis: Conservative debt structure offers resilience during economic downturns.

Healthy Liquidity Position (Current Ratio: 4.45)

Observation: Strong short-term liquidity to meet obligations.

Analysis: Current ratio >1.5 indicates good working capital management.

Balanced Promoter Holding (65.99%)

Observation: Optimal balance between promoter control and public float.

Analysis: Promoter holding in 50-75% range provides management alignment.

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral.

Analysis: Absence of share pledging eliminates potential forced-selling pressure.

Risk Factors

11 factors identified

Below-Average Return on Equity (0.59%)

Observation: Returns on equity are below industry benchmarks.

Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.

Suboptimal ROCE (3.47%)

Observation: Returns on capital employed are below expectations.

Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.

Premium Valuation Risk (P/E: 51.84x)

Observation: High valuation multiples may limit upside potential.

Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.

Profit Decline Concern (-92.94%)

Observation: Significant year-over-year profit contraction observed.

Analysis: Declining profitability requires investigation into underlying causes.

Limited Growth History (3.15% CAGR)

Observation: Below-average 5-year sales growth trajectory.

Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.

Weak Earnings Growth (-63.13% CAGR)

Observation: Below-average 5-year EPS growth performance.

Analysis: Low EPS growth may not keep pace with inflation.

Stagnant Profit Growth (-47.99% CAGR)

Observation: Limited 5-year profit growth trajectory.

Analysis: Low profit growth may indicate scalability challenges or market maturity.

Weak Interest Coverage (2.36x)

Observation: Limited ability to service debt obligations from earnings.

Analysis: Low interest coverage raises concerns about financial stability.

Negative Free Cash Flow (₹-74.93 Cr over 5Y)

Observation: Cash outflows exceed inflows.

Analysis: Negative FCF requires analysis of capital expenditure cycle.

Limited Institutional Interest (FII+DII: 2.56%)

Observation: Low institutional participation may affect liquidity.

Analysis: Limited institutional interest may indicate size constraints or visibility issues.

No Dividend Distribution

Observation: Company does not currently pay dividends to shareholders.

Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.

BALAXI PHARMACEUTICALS LIMITED vs Pharmaceuticals Peers

Peer Comparison - Pharmaceuticals

Compare BALAXI PHARMACEUTICALS LIMITED with 10 other companies in the same sector

11 companies
Company Info
Fundamental
Valuation
Profitability
Financial Health
Growth
Dividend
Company
Company name
Score
Bull Run comprehensive fundamental score based on 20+ metrics
Price
Current trading price of the stock
Market Cap
Total value of all shares in the market
P/E
Price per share divided by earnings per share
ROE
Net income divided by shareholder equity
ROCE
Earnings before interest and tax divided by capital employed
Debt/Eq
Total debt divided by total equity
Profit 5Y
Average annual profit growth over 5 years
Sales 5Y
Average annual sales growth over 5 years
Dividend
Annual dividend per share divided by price per share
15.1/100
23
₹128.80
51.8
Average
0.59%
Poor
3.47%
Poor
0.2
Excellent
-47.99%
Poor
3.15%
Average
0.00%
66.4/100
1846
₹442862.79
36.6
Average
14.74%
Average
19.31%
Good
0.0
Excellent
31.64%
Excellent
11.78%
Good
0.82%
56.3/100
9394
₹248927.75
85.2
Average
16.19%
Good
20.38%
Excellent
0.0
Excellent
5.29%
Good
8.67%
Good
0.41%
51.4/100
4943
₹167300.78
79.0
Average
27.07%
Excellent
14.09%
Average
1.8
Average
11.56%
Good
11.80%
Good
0.76%
74.1/100
1114
₹111187.18
24.8
Average
19.74%
Good
21.77%
Excellent
0.4
Excellent
18.76%
Excellent
12.45%
Good
0.09%
40.2/100
1375
₹111038.98
32.9
Average
11.82%
Average
15.67%
Good
0.0
Excellent
10.03%
Good
8.01%
Good
0.90%
34.1/100
1944
₹105024.60
96.0
Average
18.19%
Good
21.35%
Excellent
0.5
Excellent
-1.89%
Poor
7.19%
Good
0.13%
24.6/100
1666
₹95873.15
26.0
Average
9.94%
Poor
14.54%
Average
0.2
Excellent
-8.07%
Poor
6.32%
Good
0.26%
41/100
1141
₹95273.50
29.5
Average
11.75%
Average
14.80%
Average
0.2
Excellent
16.54%
Excellent
12.09%
Good
0.65%
83.4/100
2074
₹94833.65
17.1
Average
26.90%
Excellent
31.80%
Excellent
0.3
Excellent
34.39%
Excellent
13.02%
Good
0.72%
61.5/100
2246
₹92759.80
45.4
Average
12.49%
Average
13.56%
Average
0.4
Excellent
10.52%
Good
18.10%
Excellent
0.04%

BALAXI PHARMACEUTICALS LIMITED PE Ratio History

Historical price-to-earnings ratio for BALAXI — last 5 years

YearEPS (₹)Price (₹)P/E Ratio
FY 20239.08₹86.479.5x
FY 20229.53₹121.4412.7x
FY 20217.63₹102.6213.5x

P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.

BALAXI PHARMACEUTICALS LIMITED Dividend History

Annual cash dividends paid by BALAXI — dividend yield N/A

Financial YearDividends Paid (₹ Cr)
FY 20230.50 Cr

Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.

BALAXI PHARMACEUTICALS LIMITED Quarterly Performance

Latest quarterly metrics for BALAXI — revenue growth and profit growth vs same quarter last year

Revenue Growth (YoY)

14.05%

Latest quarter vs same quarter previous year

Net Profit Growth (YoY)

-92.94%

Latest quarter net profit vs same quarter previous year

5-Year Revenue CAGR

3.15%

Compounded annual revenue growth over 5 years

5-Year Profit CAGR

-47.99%

Compounded annual net profit growth over 5 years

BALAXI PHARMACEUTICALS LIMITED Technical Indicators

SMA 50, SMA 200, RSI and volume signals for BALAXI — calculated from daily price history

59RSI 14
Neutral — RSI 59

Momentum is balanced — neither overbought nor oversold.

SMA 50
24
▼ Price below SMA 50 — Short-term bearish
SMA 200
25
▼ Price below SMA 200 — Long-term downtrend
30-Day Avg Volume
53K shares/day
Average daily traded volume over last 30 trading sessions

Technical indicators are for educational purposes only. Not investment advice.

BALAXI PHARMACEUTICALS LIMITED Financial Statements

Annual income statement, balance sheet and cash flow for BALAXI PHARMACEUTICALS LIMITED (BALAXI) — sourced from NSE/BSE filings.

Financial Results & Statements

Latest quarterly, annual and period-wise financial data for BALAXI PHARMACEUTICALS LIMITED

Loading latest quarterly results...

About BALAXI (BALAXI PHARMACEUTICALS LIMITED)

Balaxi Pharmaceuticals Ltd is a dynamic and expanding player in the global pharmaceutical landscape, focusing on bridging critical healthcare gaps in emerging markets. With a stead...fast commitment to quality and accessibility, Balaxi operates as an international distributor, meticulously sourcing and delivering essential pharmaceutical products to regions often underserved by mainstream pharmaceutical companies. Beyond traditional distribution, Balaxi cultivates strong, localized partnerships, building robust supply chains and tailoring product offerings to meet the specific needs and regulatory landscapes of each market. Their comprehensive approach ensures that vital medications reach patients who need them most, improving health outcomes and fostering long-term relationships with healthcare providers and communities. The company's core strength lies in its diverse therapeutic portfolio, encompassing a wide range of treatments addressing prevalent health challenges in its target regions. From life-saving antibiotics combating infectious diseases to effective analgesics alleviating pain and suffering, and vital anti-malarial medications fighting the scourge of malaria, Balaxi's product range reflects its dedication to improving public health. Beyond pharmaceuticals, Balaxi recognizes the importance of holistic well-being, extending its reach into fast-moving consumer goods (FMCG) to provide essential daily necessities. This diversified approach allows Balaxi to cater to a broader range of needs within the communities it serves, further solidifying its role as a trusted and reliable partner. Balaxi Pharmaceuticals Ltd is driven by a vision of sustainable growth and social responsibility. The company's strategic focus on emerging markets, combined with its commitment to quality, innovation, and ethical business practices, positions it for continued success in the evolving global healthcare landscape. By fostering strong relationships with manufacturers, distributors, and local communities, Balaxi is building a robust and resilient business model that delivers value to all stakeholders. With a clear mission to improve access to essential medicines and consumer goods, Balaxi Pharmaceuticals Ltd is making a tangible difference in the lives of people across Africa, the Caribbean Islands, and Latin America.

Company Details

Symbol:BALAXI
Industry:Pharmaceuticals
Sector:Pharmaceuticals

BALAXI Share Price: Frequently Asked Questions

What is the current share price of BALAXI PHARMACEUTICALS LIMITED?

BALAXI PHARMACEUTICALS LIMITED (BALAXI) trades at ₹23.33 on NSE. Market cap ₹128.80 (Cr). Educational data only.

What is the P/E ratio of BALAXI PHARMACEUTICALS LIMITED?

BALAXI PHARMACEUTICALS LIMITED has a P/E of 51.84x vs industry average 34.89x.

What is the Bull Run score for BALAXI PHARMACEUTICALS LIMITED?

BALAXI PHARMACEUTICALS LIMITED has a Bull Run score of 15.1/100 based on 25+ financial parameters.

Does BALAXI PHARMACEUTICALS LIMITED pay dividends?

BALAXI PHARMACEUTICALS LIMITED has a dividend yield of 0.00%. Past dividends don't guarantee future payments.

What is the ROE of BALAXI PHARMACEUTICALS LIMITED?

BALAXI PHARMACEUTICALS LIMITED has ROE of 0.59%. Higher ROE indicates better use of shareholder equity.

What is the debt-to-equity ratio of BALAXI PHARMACEUTICALS LIMITED?

BALAXI PHARMACEUTICALS LIMITED has debt-to-equity of 0.22.

Is BALAXI PHARMACEUTICALS LIMITED a good investment?

Bull Run gives BALAXI PHARMACEUTICALS LIMITED a score of 15.1/100. This is not investment advice — consult a SEBI-registered advisor.